Comparison of clinical and laboratory features between immunotherapy responding chronic axonal polyneuropathy (IR-CAP) and chronic inflammatory demyelinating polyneuropathy (CIDP)
| Features | IR-CAP (N=33) | CIDP (N=58)* |
| Sex: male/female | 15/18 | 19/39 |
| Mean (range) age, years | 57.2 (27–79) | 44.4 (4–79) |
| Mean duration (range) of progression, months | 10.5 (2–84) | 15.1 (2.1–300) |
| Previous episodes | 5 (15%) | 12 (21%) |
| Antecedent infection or event | 8 (24%) | 8 (14%) |
| Clinical subtypes | ||
| Motor sensory | 30 (91%) | 37 (64%) |
| Symmetrical | 26 (79%) | 30 (52%) |
| Asymmetrical | 4 | 7 |
| Motor | 2† | 18† |
| Symmetrical | 2 (5%) | 15 (26%) |
| Asymmetrical | 0 | 3 |
| Sensory | 1 | 4 |
| Symmetrical | 1 | 3 |
| Asymmetrical | 0 | 1 |
| Proximal muscle weakness | 25 (76%) | 39 (67%) |
| Cranial nerve involvement | 6 | 3 |
| Respiratory failure | 2 | 1 |
| Relapse | 14 (42%) | 29 (50%) |
| Spontaneous improvement | 0 | 0 |
| High spinal fluid protein, mg/dL | ||
| Mean (range) | 97.7 (32–660) | 99.4 (18–770) |
| >55 (high) | 25/32 (78%) | 32/49 (65%) |
| Response to treatment | ||
| No improvement | 6/51 (12%) | |
| Improvement to normal | 7/33 (21%) | 16/53 (30%) |
| Disability score (SD) | ||
| At onset | 6.65 | 6.83 |
| At best improvement | 3.43 | 2.65 |
| % mean improvement | 48% | 61% |
*Cited from reference.6
†P =0.0057 for motor types (symmetrical and asymmetrical motor).